EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The phospho-tau cascade, basal forebrain neurodegeneration, and dementia in Alzheimer's disease: Anti-neurodegenerative benefits of acetylcholinesterase inhibitors

Donald E Moss iD, Ruth G Perez

Journal of Alzheimer’s Disease · 2024

DOI: 10.1177/13872877241289602 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Donald E Moss und 1 weiteren Autor:innen. Beteiligte Einrichtung: Professor Emeritus, University of Texas at El Paso, El Paso, TX, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Basal Forebrain, Cholinesterase Inhibitors, tau Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A conundrum in Alzheimer's disease (AD) is why the long-term use of acetylcholinesterase (AChE) inhibitors, intended for treatment of dementia, results in slowing neurodegeneration in the cholinergic basal forebrain, hippocampus, and cortex. The phospho-tau cascade hypothesis presented here attempts to answer that question by unifying three hallmark features of AD into a specific sequence of events. It is proposed that the hyperphosphorylation of tau protein leads to the AD-associated deficit of nerve growth factor (NGF), then to atrophy of the cholinergic basal forebrain and dementia. Because the release of pro-nerve growth factor (pro-NGF) is activity-dependent and is controlled by basal forebrain projections to the hippocampus and cortex, our hypothesis is that AChE inhibitors act by increasing acetylcholine-dependent pro-NGF release and, thus, augmenting the availability of mature NGF and improving basal forebrain survival. If correct, improved central nervous system-selective AChE inhibitor therapy started prophylactically, before AD-associated basal forebrain atrophy and cognitive impairment onset, has the potential to delay not only the onset of dementia but also its rate of advancement. The phospho-tau hypothesis thus suggests that preventing hyperphosphorylation of tau protein, early should be a high priority as a strategy to help reduce dementia and its associated widespread social and economic suffering.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBasal ForebrainCholinesterase Inhibitorstau ProteinsAnimalsHumansDementiaNerve DegenerationPhosphorylationProsencephalonSignal Transduction

Stichwörter der Autor:innen

Alzheimer's diseaseacetylcholinesterase inhibitorsdementianerve growth factorpro-NGFtau phosphorylation

Substanzen

Cholinesterase Inhibitorstau Proteins

Autor:innen und Institutionen

  • Professor Emeritus, University of Texas at El Paso, El Paso, TX, USA.
  • CEO, R&R Perez LLC, El Paso, TX, USA.

ORCID-Profile: Donald E Moss

Zitieren

APA

Moss, D. E., & Perez, R. G. (2024). The phospho-tau cascade, basal forebrain neurodegeneration, and dementia in Alzheimer's disease: Anti-neurodegenerative benefits of acetylcholinesterase inhibitors. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241289602

Vancouver

Moss DE, Perez RG. The phospho-tau cascade, basal forebrain neurodegeneration, and dementia in Alzheimer's disease: Anti-neurodegenerative benefits of acetylcholinesterase inhibitors. Journal of Alzheimer’s Disease. 2024. doi:10.1177/13872877241289602

BibTeX
@article{Moss2024,
  author = {Moss, Donald E and Perez, Ruth G},
  title = {The phospho-tau cascade, basal forebrain neurodegeneration, and dementia in Alzheimer's disease: Anti-neurodegenerative benefits of acetylcholinesterase inhibitors},
  journal = {Journal of Alzheimer’s Disease},
  year = {2024},
  doi = {10.1177/13872877241289602}
}
Kostenlos starten →